S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Price, News & Analysis

$1.98
-0.04 (-1.98%)
(As of 03/1/2024 ET)
Today's Range
$1.97
$2.05
50-Day Range
$1.90
$2.85
52-Week Range
$1.11
$3.85
Volume
92,603 shs
Average Volume
244,966 shs
Market Capitalization
$160.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.72

ProQR Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.7% Upside
$3.72 Price Target
Short Interest
Healthy
0.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of ProQR Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.22) to ($0.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

755th out of 950 stocks

Pharmaceutical Preparations Industry

336th out of 423 stocks


PRQR stock logo

About ProQR Therapeutics Stock (NASDAQ:PRQR)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Stock Price History

PRQR Stock News Headlines

PRQR Mar 2024 2.500 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ProQR Therapeutics N.V.
4 Biotech Stocks With Massive Buy Potential
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Is ProQR (PRQR) Stock a Solid Choice Right Now?
ProQR Therapeutics NV PRQR
Positive Report for ProQR (PRQR) from Chardan Capital
ProQR Therapeutics Provides Update on Ophthalmic Assets
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/02/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRQR
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.72
High Stock Price Target
$5.00
Low Stock Price Target
$1.80
Potential Upside/Downside
+87.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-68,600,000.00
Net Margins
-831.30%
Pretax Margin
-832.57%

Debt

Sales & Book Value

Annual Sales
$4.25 million
Book Value
$0.85 per share

Miscellaneous

Free Float
74,028,000
Market Cap
$160.02 million
Optionable
Optionable
Beta
0.20

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Domenico Valerio Ph.D. (Age 68)
    Founder & Independent Chairman of Supervisory Board
    Comp: $80.18k
  • Mr. Daniel Anton de Boer (Age 41)
    Founder, CEO & Member of Management Board
    Comp: $1.43M
  • Mr. Rene K. Beukema (Age 60)
    Chief Corporate Development Officer, General Counsel & Member of Management Board
    Comp: $318.55k
  • Dr. Gerard Platenburg (Age 60)
    Co-Founder & Chief Scientific Officer
    Comp: $23.84k
  • Mr. Jurriaan Dekkers (Age 48)
    Chief Financial Officer
  • Ms. Sheila Sponselee (Age 40)
    Chief People & Operations Officer
  • Ms. Sarah Cue Kiely
    Vice President of Investor Relations & Corporate Communications
  • Ms. Sandra van der Kolk
    Junior Financial Controller














PRQR Stock Analysis - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings
or view top-rated stocks.

What is ProQR Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued 1 year price objectives for ProQR Therapeutics' shares. Their PRQR share price targets range from $1.80 to $5.00. On average, they predict the company's share price to reach $3.72 in the next year. This suggests a possible upside of 87.7% from the stock's current price.
View analysts price targets for PRQR
or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2024?

ProQR Therapeutics' stock was trading at $1.98 on January 1st, 2024. Since then, PRQR shares have increased by 0.0% and is now trading at $1.98.
View the best growth stocks for 2024 here
.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our PRQR earnings forecast
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.80 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 60.65% and a negative net margin of 831.30%.

What ETF holds ProQR Therapeutics' stock ?

Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.04%), BNP Paribas Financial Markets (0.02%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRQR) was last updated on 3/2/2024 by MarketBeat.com Staff